Enteroviruses (EV), especially group B coxsackieviruses (CVB), are considered a common cause of acute myocarditis in children and young adults, a disease which is a precursor to 10 to 20% of chronic myocarditis cases as well as dilated cardiomypathy (prevalence = 7 cases/100,000), characterized by an increase in both myocardial mass and volume, compromising cardiac contractility and ultimately resulting in poor left ventricular function (8, 9, 12, 14). Dilated cardiomypathy is considered to be the second leading cause of heart transplantation worldwide after ischemic heart disease. The concept that persistent endomyocardial EV infection could be the etiologic cause of a subset of idiopathic dilated cardiomypathy (IDCM) cases is supported by the detection in up to 35% of explanted heart tissues from end-stage IDCM patients of EV RNA and the viral capsid protein VP1 in the absence of viruses that can be cultivated by classical techniques (2, 3, 13). However, the viral molecular mechanisms involved in the progression of acute myocarditis to chronic myocarditis and subsequently to IDCM are currently poorly understood. In 2008, Chapman et al. (7) reported for the first time the isolation from human heart tissue of a CVB2 strain with genomic 5’-terminal deletions (TD). These mutations induced significant slowing of viral replication and a lowering of virus titer in cell culture models where an absence of classical cytopathic effects was associated with an abnormal positive- to negative-strand viral RNA ratio close to 1 rather than the high positive- to negative-strand ratios normally seen in wild-type virus infected cells (11). These findings demonstrated the existence of unexpected EV-TD genomic populations in clinical samples, thereby a mechanism by which EV can persist in heart long after the acute infection cycle.

In this context, the aim of the present study was to validate a sensitive and standardized one-step real-time RT-PCR assay capable of detecting and quantifying EV RNA (both positive and negative strands) of wild-type as well as TD EV strains in cardiac tissue samples obtained from IDCM patients. Reverse transcription and PCR were carried out using a Superscript III Platinum one-step quantitative reverse transcription-PCR (qRT-PCR) kit (Invitrogen, Life Technologies, Saint-Aubin, France) containing 200 nM forward primer (5’-CCGTGAATG CGGCTAATCC-3’, positions 456 to 474), 200 nM reverse primer (5’-ATTTGTCACCATAGCGAGCCA-3’, positions 582 to 601), and 100 nM probe (FAM-5’-AACCGACTACTTTGGGTGTCCG TGTTTC-3’-TAMRA, positions 539 to 566) (17). Reverse transcription was performed at 55°C for 45 min, the RT was heat inactivated at 95°C for 2 min, and then the cDNA was amplified in 45 cycles as follows: denaturation at 94°C for 15 s, annealing at 63°C for 1 min, and an extension step at 68°C for 30 s. To validate detection and quantitation of EV in cardiac biopsy specimens, serial dilutions of positive- and negative-strand transcripts of wild-type and TD CVB3 clones kindly provided by N. M. Chapman (University of Nebraska Medical Center, Omaha, NE) were tested. Both wild-type and TD positive- and negative-strand RNA molecules were detected in vitro by the one-step RT-PCR assay. The sensitivity and the reproducibility of the RT-PCR assay were then determined using serial 10-fold dilutions of the transcripts ranging from 3 × 10^6 to 30 copies diluted in DNA and RNA extracts of EV-negative cardiac tissues with similar results in terms of standard curves, regardless of the transcripts used for the experiments. The threshold of viral RNA detection was found repeatedly to be 30 copies per well for both wild-type and TD EV RNA transcripts for both positive- and negative-strand RNAs. This sensitivity of detection, is crucial because TD mutants replicate slowly and to low titers (7, 10, 11). This will be important for future work and may explain past inability to detect RNA despite viral capsid protein VP1 detection (1).

Being able to quantitate both positive- and negative-strand viral RNA titers in clinical samples would permit the measurement of the positive- to negative-strand viral RNA ratio to facilitate an assessment of EV persistence mechanisms potentially associated with the development of IDCM. To validate the specific negative-strand viral RNA isolation, a time course of CVB3 replication model was performed in MA-104 cells (rhesus monkey kidney cell
line), which were infected at a multiplicity of infection of 1 50% tissue culture infective dose (TCID₅₀) with the CVB3 prototype strain Nancy and collected at 0, 2, 8, 10, 14, and 24 h postinfection. Negative-strand RNA was isolated from total RNA molecules by annealing a biotinylated negative-strand specific primer (E3REV; 5'-GGAACCGACTACTTTGGGTGTCCGTG-3') and binding to streptavidin-labeled magnetic beads (Invitrogen, Life Technologies, Saint-Aubin, France) (7, 11). Purified negative-strand and total viral RNA molecules were quantified with a one-step real-time RT-PCR assay using serial dilutions of the transcripts for the generation of the standard curves. The positive- to negative-strand viral RNA ratio was then determined using the following calculation: (total EV RNA − negative-strand EV RNA)/negative-strand EV RNA. Positive- to negative-strand viral RNA ratios assessed at 8 h and 24 h postinfection were 96 and 85, respectively, consistent with the high positive-to-negative ratios normally seen in wild-type-virus-infected-cell models (Fig. 1).

Ninety-nine paraffin-embedded cardiac biopsy specimens collected by the department of pathology of the European Hospital Georges Pompidou (Paris, France) were investigated. These samples were explanted heart tissue samples collected between 2000 and 2009 from a population of 20 adult patients demonstrating histological findings compatible with IDCM (4). As control samples, heart tissue was selected from 10 adult patients who had died accidentally or by suicide (CHU, Reims France). EV RNA was detected in 6 (9%) of the 99 samples analyzed, corresponding to 4 (20%) of the 20 IDCM patients, whereas no viral RNA was detected in the heart tissue samples taken from the 10 control subjects. These results confirm those published by our group and others that have reported EV RNA detection in up to 35% of cardiac explants in subjects with IDCM (2, 5, 9, 13). The median viral load assessed was 287 copies/μg of total extracted nucleic acids, with a range of 10 to 3,368 copies/μg (Table 1). These results are in agreement with those obtained from murine heart tissues chronically infected with CVB3 (3, 15). In contrast, this median viral load was 500 times lower than that obtained in our model of MA-104 cells (1.83 × 10⁵ copies) infected with the wild-type CVB3 Nancy strain, which produces an acute and lytic viral infection (Fig. 1).

Negative-strand RNA molecules were detected in the four EV-positive IDCM patients. The ratios observed in explanted heart tissues samples ranged from 2 to 20, indicating several levels of viral genome replication activities, though all were consistent with a chronic viral infection (Table 1). These ratios were closer to those observed (4/1) in a persistent CVB infection of muscle in mice afflicted with chronic inflammatory myopathy (16). Moreover, they are also consistent with CVB TD strain infections, which were previously reported to have low levels of viral replication, with positive- to negative-strand viral RNA ratios of 2 to 3 in chronically infected mice and humans (7, 11). In contrast, the experimental curve obtained in the MA-104 cell infection model revealed an average positive- to negative-strand viral RNA ratio of 47/1, which is in accordance with ratios previously observed (40/1 to 75/1) in similar cellular models of active EV infections (11, 16).

In summary, a standardized one-step real-time RT-PCR assay was validated for wild-type and TD EV strains detection in human heart tissues. This reliable method detected EV RNA in up to 20%

![FIG 1](http://jcm.asm.org/)

**FIG 1** Levels of total viral RNA and negative-strand viral RNA and positive- to negative-strand viral RNA ratios during the first 24 h of CVB3 replication in MA-104 cells.

<p>| TABLE 1 EV RNA loads and viral RNA ratios assessed in the four EV-positive IDCM patients |
|---------------------------------|---------------------------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Patient</th>
<th>Cardiac anatomic location</th>
<th>EV RNA load (copies/μg of total extracted RNA)</th>
<th>Ratio of positive- to negative-strand viral RNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Septum</td>
<td>127 40</td>
<td>2.2</td>
</tr>
<tr>
<td></td>
<td>Septum</td>
<td>357 120</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Septum</td>
<td>217 61</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Right ventricle</td>
<td>183 45</td>
<td>3.1</td>
</tr>
<tr>
<td>3</td>
<td>Right ventricle</td>
<td>2,108 347</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>Left ventricle</td>
<td>3,368 160</td>
<td>20</td>
</tr>
</tbody>
</table>
of IDCM patients, in agreement with previously published studies. Moreover, this quantitative molecular tool provided information fundamental to the diagnosis and understanding of EV cardiac infections by demonstrating low viral loads and low positive- to negative-strand RNA ratios in the human heart samples analyzed, which were clearly consistent with chronic or persistent viral infection (2, 6, 13). Further experiments using molecular cloning and sequencing of the 5′ nontranslated region (NTR) of the EV strains detected in IDCM patients are under way and will help identify and characterize the potential presence of EV strains presenting with terminal deletions in the 5′ NTR.

ACKNOWLEDGMENTS

Fanny Renois is supported by an official grant from the French Army department (Bourse DGA: Délégation Générale de l’Armement, Ministère de la Défense, Topic: Microbiology, infectious diseases, 2009–2012).

We thank N. M. Chapman and S. Tracy for graciously reading the manuscript prior to submission for publication.

None of the authors has a commercial or other association that might pose a conflict of interest (e.g., pharmaceutical stock ownership or consultancy). This work was supported in part by a grant for Clinical and Virological research (SFR-CAP santé /EA-4684) from the Medical University and School of Medicine of Reims, France. No extra funding was used. There is no commercial relationship or any potential conflict of interest of any nature.

REFERENCES


